Navigation Links
Oramed Pharmaceuticals Chosen to Present at the Diabetes Technology Meeting (October 27-29, 2011; San Francisco, CA)
Date:10/25/2011

JERUSALEM, October 25, 2011 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that its work entitled "Evaluation of the Safety and Efficacy of Two Oral Insulin Formulations in Healthy Volunteers" will be presented at the Eleventh Annual Meeting of the Diabetes Technology Society, to be held in San Francisco, California.

"The selection of Oramed as one of the companies to present at the Diabetes Technology Conference is a great opportunity for us to appraise the diabetes science community on the important progress we have made," said Dr Miriam Kidron, Oramed's Chief Scientific Officer.

Oramed's poster will be presented on Thursday October 27, 2011, at 4:05-6:30 PM.

For more information about the Diabetes Technology Society's Eleventh Annual Meeting, please visit http://www.diabetestechnology.org/dtm.shtml

For more information about Oramed Pharmaceuticals, please visit http://www.oramed.com

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection.  Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com 
 

Forward-looking statements

Some of the statements contained in this press release are forw
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
2. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
3. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
4. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
5. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
6. Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
7. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
8. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
9. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
10. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
11. Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is ... of partially hydrolyzed gluten in foods, has been accepted by AOAC International as ... Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a ...
(Date:7/30/2015)... Mass. , July 30, 2015   ... solutions for the interpretation and analysis of genomic ... Matthew Fischer has joined the company as ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... capabilities to integrate, interpret, analyze and explore complex ...
(Date:7/30/2015)... -- According to a new market research ... PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), by ... End Users - Global Forecast to 2020", published by ... 2,107.99 million by 2020 from USD 1,034.93 million in ... Browse more than 75 market ...
(Date:7/30/2015)... DIEGO, July 30, 2015   Senomyx , Inc. ... taste science technologies to discover, develop, and commercialize novel ... industries, today reported financial results for the second quarter ... of 2015, we remain on track to achieve our ... Chief Executive Officer of the Company. "Since our last ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... 13 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ... on commercializing proprietary product candidates for the ... that Evan M. Levine,ADVENTRX,s chief executive officer, ... Fifth Annual Growth Conference on Wednesday,September 19th, ...
... ... to inhibit ... 13, 9:45 a.m. EDT at ... http://www.isispharm.com , CARLSBAD, Calif., Sept. 13 Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ...
... VANCOUVER, Sept. 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. ... today that it received a,favourable decision from ... an attempt by Johnson & Johnson,s subsidiary, ... Zealand Patent 523799, which,pertains to compositions comprising ...
Cached Biology Technology:ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners' Fifth Annual Growth Conference 2Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 2Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 3Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 4Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 5Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 2Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 3Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 4
(Date:7/21/2015)... , July 21, 2015 Passwords have ... seen in the recent U.S. Office of Personnel ... to the infosec conundrum, but developers and end-users ... To address this dilemma, Biometrics-as-a-Service provider HYPR Corp. ... Tokenization SDK for third party integration. ...
(Date:7/13/2015)... , July 13, 2015 Synaptics Inc. ... human interface solutions, today announced sampling of ClearPad ... display driver integration (TDDI) product targeting smartphones and ... to combine Synaptics , best-in-class touch controller ... driver technology developed in the company,s Japan Design ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... The changes to the publication requirements of new ... XVIII International Botanical Congress in Melbourne in July 2011 ... To address practical questions arising from the Congress decisions, the ... a series of seven exemplar papers, one each day for ...
... the Greek word for "glue," hold the brain,s neurons together ... but scientists have long puzzled over their prominence in the ... Tel Aviv University researchers say that glia cells are central ... and stores information. According to Ph.D. student Maurizio ...
... the Gobi desert are usually long and very cold ... of livestock died in Mongolia and the re-introduced wild ... Walzer from the University of Veterinary Medicine, Vienna have ... GPS telemetry to provide insights into the effect of ...
Cached Biology News:Brave new world 2Brave new world 3Brain's connective cells are much more than glue 2Brain's connective cells are much more than glue 3Don't put all your eggs in 1 basket -- or all your horses on 1 pasture 2Don't put all your eggs in 1 basket -- or all your horses on 1 pasture 3
Complete cell culture media with cytokines...
... normal multiple tissue panels are designed ... of genes or proteins of interest ... mounted on positively charged glass slides. ... in the identical format, and cDNA ...
8 different frozen tissues are mounted on positively charged glass slides...
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
Biology Products: